Royal Bank of Canada’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$184K Buy
1,661
+1,599
+2,579% +$145K ﹤0.01% 5045
2026
Q1
$5K Sell
62
-1,614
-96% -$157K ﹤0.01% 6441
2025
Q4
$180K Sell
1,676
-124,110
-99% -$13.2M ﹤0.01% 4830
2025
Q3
$12.7M Sell
125,786
-70,450
-36% -$6.54M ﹤0.01% 1974
2025
Q2
$12.4M Buy
196,236
+196,105
+149,698% +$12M ﹤0.01% 1868
2025
Q1
$7K Sell
131
-1,083
-89% -$60.1K ﹤0.01% 6273
2024
Q4
$68K Sell
1,214
-5,071
-81% -$280K ﹤0.01% 5539
2024
Q3
$328K Buy
6,285
+836
+15% +$40.1K ﹤0.01% 4431
2024
Q2
$223K Buy
5,449
+4,005
+277% +$160K ﹤0.01% 4673
2024
Q1
$63K Sell
1,444
-14,688
-91% -$643K ﹤0.01% 5436
2023
Q4
$743K Buy
16,132
+4,089
+34% +$129K ﹤0.01% 3913
2023
Q3
$276K Buy
12,043
+4,794
+66% +$107K ﹤0.01% 4524
2023
Q2
$120K Buy
7,249
+5,286
+269% +$95.4K ﹤0.01% 5186
2023
Q1
$35K Buy
1,963
+1,789
+1,028% +$44.9K ﹤0.01% 5803
2022
Q4
$5K Buy
174
+109
+168% +$2.8K ﹤0.01% 6744
2022
Q3
$2K Buy
+65
New +$1.21K ﹤0.01% 7060
2022
Q2
Sell
-2,796
Closed -$32K 7669
2022
Q1
$32K Sell
2,796
-5,735
-67% -$50.3K ﹤0.01% 6352
2021
Q4
$85K Buy
8,531
+3,951
+86% +$44.4K ﹤0.01% 6051
2021
Q3
$60K Buy
4,580
+363
+9% +$5.54K ﹤0.01% 6055
2021
Q2
$83K Buy
4,217
+402
+11% +$8.35K ﹤0.01% 5730
2021
Q1
$81K Buy
3,815
+3,160
+482% +$91.6K ﹤0.01% 5597
2020
Q4
$20K Buy
655
+455
+228% +$11.6K ﹤0.01% 6072
2020
Q3
$4K Buy
+200
New +$4.58K ﹤0.01% 6187
2020
Q2
Sell
-121
Closed -$2K 6870
2020
Q1
$2K Sell
121
-1,631
-93% -$29.2K ﹤0.01% 6325
2019
Q4
$40K Buy
+1,752
New +$38.9K ﹤0.01% 5545
2019
Q2
Sell
-5
Closed 7130
2019
Q1
$0 Buy
5
+3
+150% +$86 ﹤0.01% 7049
2018
Q4
$0 Sell
2
-424
-100% -$11.7K ﹤0.01% 7058
2018
Q3
$12K Buy
426
+380
+826% +$12K ﹤0.01% 5911
2018
Q2
$1K Buy
+46
New +$1.26K ﹤0.01% 6386
2018
Q1
Sell
-106
Closed -$3K 6728
2017
Q4
$3K Buy
+106
New +$2.8K ﹤0.01% 6209

Other funds holding RYTM

Royal Bank of Canada's RYTM Position: Q2 2026 in Review

Royal Bank of Canada increased its Rhythm Pharmaceuticals (RYTM) stake by 2,579% in Q2 2026, buying an estimated $145K and bringing the position to 1,661 shares worth $184K. The position accounts for ﹤0.01% of the portfolio, ranked #5045.

Royal Bank of Canada first reported a position in RYTM in Q4 2017 and has held it in 30 quarters since. The position peaked at $12.7M in Q3 2025. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Royal Bank of Canada held 1,661 shares of Rhythm Pharmaceuticals worth $184K as of Q2 2026.
  • Royal Bank of Canada bought 1,599 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $145K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #5045 holding.
  • Royal Bank of Canada first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 30 quarters since.
  • Royal Bank of Canada's Rhythm Pharmaceuticals position peaked at $12.7M in Q3 2025.
  • 302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.